Suggested remit - To appraise the clinical and cost effectiveness of ERC1671 within its marketing authorisation for treating glioblastoma in adults with disease that has progressed or recurred following treatment with radiotherapy and temozolomide
The company has been unable to source all the necessary evidence to provide a submission that meets the requirements of the scope for this appraisal within the required timelines. Therefore the company and NICE have agreed to put the appraisal on hold. Consequently the discussion of this appraisal at the committee meeting scheduled on 14 July 2020 will not take place. We will update you on our progress and next steps for this appraisal as soon as possible.
 
Status Suspended
Decision Selected
Process STA 2018
ID number 1623

Project Team

Project lead Thomas Feist

Email enquiries

Stakeholders

Companies sponsors ERC - Epitopoietic Research Corporation
Patient carer groups The Brain Tumour Charity
  Braintrust
Professional groups Association of British Neurologists
  Cancer Research
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
General commentators All Wales Therapeutics & Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
06 May 2020 Suspended. The company has been unable to source all the necessary evidence to provide a submission that meets the requirements of the scope for this appraisal within the required timelines. Therefore the company and NICE have agreed to put the appraisal on hold. Consequently the discussion of this appraisal at the committee meeting scheduled on 14 July 2020 will not take place. We will update you on our progress and next steps for this appraisal as soon as possible.
11 November 2019 Invitation to participate
14 October 2019 (10:00) Scoping workshop (Manchester)
19 August 2019 - 17 September 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 May 2019 In progress. Referred 29 April 2019

For further information on our processes and methods, please see our CHTE processes and methods manual